Future cancer research priorities in the USA: a Lancet Oncology Commission

Elizabeth M. Jaffee; Chi Van Dang; David B. Agus; Brian M. Alexander; Kenneth C. Anderson; Alan Ashworth; Anna Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A. Bluestone; Otis Brawley; Atul J. Butte; Daniel G. Coit; Nancy E. Davidson; Mark Davis; Ronald A. DePinho; Robert B. Diasio; Giulio Draetta; A. Lindsay Frazier; Andrew Futreal; Sam S. Gambhir; Patricia A. Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I. Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh Thu Le; Scott M. Lippman; David Mankoff; Elaine R. Mardis; Deborah K. Mayer; Kelly McMasters; Neal J. Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M. Pawlik; Jeffrey Peppercorn; Martin G. Pomper; Derek Raghavan; Christine Ritchie; Sally W. Schwarz; Richard Sullivan; Richard Wahl; Jedd D. Wolchok; Sandra L. Wong; Alfred Yung

doi:10.1016/S1470-2045(17)30698-8

Future cancer research priorities in the USA: a Lancet Oncology Commission

Elizabeth M. Jaffee, Chi Van Dang, David B. Agus, Brian M. Alexander, Kenneth C. Anderson, Alan Ashworth, Anna Barker, Roshan Bastani, Sangeeta Bhatia, Jeffrey A. Bluestone, Otis Brawley, Atul J. Butte, Daniel G. Coit, Nancy E. Davidson, Mark Davis, Ronald A. DePinho, Robert B. Diasio, Giulio Draetta, A. Lindsay Frazier, Andrew FutrealSam S. Gambhir, Patricia A. Ganz, Levi Garraway, Stanton Gerson, Sumit Gupta, James Heath, Ruth I. Hoffman, Cliff Hudis, Chanita Hughes-Halbert, Ramy Ibrahim, Hossein Jadvar, Brian Kavanagh, Rick Kittles, Quynh Thu Le, Scott M. Lippman, David Mankoff, Elaine R. Mardis, Deborah K. Mayer, Kelly McMasters, Neal J. Meropol, Beverly Mitchell, Peter Naredi, Dean Ornish, Timothy M. Pawlik, Jeffrey Peppercorn, Martin G. Pomper, Derek Raghavan, Christine Ritchie, Sally W. Schwarz, Richard Sullivan, Richard Wahl, Jedd D. Wolchok, Sandra L. Wong, Alfred Yung

Complex Adaptive Systems (CAS)

Research output: Contribution to journal › Review article › peer-review

122 Scopus citations

Abstract

We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.

Original language	English (US)
Pages (from-to)	e653-e706
Journal	The Lancet Oncology
Volume	18
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(17)30698-8
State	Published - Nov 2017

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(17)30698-8

Cite this

Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A., Bastani, R., Bhatia, S., Bluestone, J. A., Brawley, O., Butte, A. J., Coit, D. G., Davidson, N. E., Davis, M., DePinho, R. A., Diasio, R. B., Draetta, G., Frazier, A. L., ... Yung, A. (2017). Future cancer research priorities in the USA: a Lancet Oncology Commission. The Lancet Oncology, 18(11), e653-e706. https://doi.org/10.1016/S1470-2045(17)30698-8

Jaffee, EM, Dang, CV, Agus, DB, Alexander, BM, Anderson, KC, Ashworth, A, Barker, A, Bastani, R, Bhatia, S, Bluestone, JA, Brawley, O, Butte, AJ, Coit, DG, Davidson, NE, Davis, M, DePinho, RA, Diasio, RB, Draetta, G, Frazier, AL, Futreal, A, Gambhir, SS, Ganz, PA, Garraway, L, Gerson, S, Gupta, S, Heath, J, Hoffman, RI, Hudis, C, Hughes-Halbert, C, Ibrahim, R, Jadvar, H, Kavanagh, B, Kittles, R, Le, QT, Lippman, SM, Mankoff, D, Mardis, ER, Mayer, DK, McMasters, K, Meropol, NJ, Mitchell, B, Naredi, P, Ornish, D, Pawlik, TM, Peppercorn, J, Pomper, MG, Raghavan, D, Ritchie, C, Schwarz, SW, Sullivan, R, Wahl, R, Wolchok, JD, Wong, SL & Yung, A 2017, 'Future cancer research priorities in the USA: a Lancet Oncology Commission', The Lancet Oncology, vol. 18, no. 11, pp. e653-e706. https://doi.org/10.1016/S1470-2045(17)30698-8

@article{3907bbb7dc284561a99cec7c5dd60cf5,

title = "Future cancer research priorities in the USA: a Lancet Oncology Commission",

abstract = "We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.",

author = "Jaffee, {Elizabeth M.} and Dang, {Chi Van} and Agus, {David B.} and Alexander, {Brian M.} and Anderson, {Kenneth C.} and Alan Ashworth and Anna Barker and Roshan Bastani and Sangeeta Bhatia and Bluestone, {Jeffrey A.} and Otis Brawley and Butte, {Atul J.} and Coit, {Daniel G.} and Davidson, {Nancy E.} and Mark Davis and DePinho, {Ronald A.} and Diasio, {Robert B.} and Giulio Draetta and Frazier, {A. Lindsay} and Andrew Futreal and Gambhir, {Sam S.} and Ganz, {Patricia A.} and Levi Garraway and Stanton Gerson and Sumit Gupta and James Heath and Hoffman, {Ruth I.} and Cliff Hudis and Chanita Hughes-Halbert and Ramy Ibrahim and Hossein Jadvar and Brian Kavanagh and Rick Kittles and Le, {Quynh Thu} and Lippman, {Scott M.} and David Mankoff and Mardis, {Elaine R.} and Mayer, {Deborah K.} and Kelly McMasters and Meropol, {Neal J.} and Beverly Mitchell and Peter Naredi and Dean Ornish and Pawlik, {Timothy M.} and Jeffrey Peppercorn and Pomper, {Martin G.} and Derek Raghavan and Christine Ritchie and Schwarz, {Sally W.} and Richard Sullivan and Richard Wahl and Wolchok, {Jedd D.} and Wong, {Sandra L.} and Alfred Yung",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2017",

month = nov,

doi = "10.1016/S1470-2045(17)30698-8",

language = "English (US)",

volume = "18",

pages = "e653--e706",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "11",

}

TY - JOUR

T1 - Future cancer research priorities in the USA

T2 - a Lancet Oncology Commission

AU - Jaffee, Elizabeth M.

AU - Dang, Chi Van

AU - Agus, David B.

AU - Alexander, Brian M.

AU - Anderson, Kenneth C.

AU - Ashworth, Alan

AU - Barker, Anna

AU - Bastani, Roshan

AU - Bhatia, Sangeeta

AU - Bluestone, Jeffrey A.

AU - Brawley, Otis

AU - Butte, Atul J.

AU - Coit, Daniel G.

AU - Davidson, Nancy E.

AU - Davis, Mark

AU - DePinho, Ronald A.

AU - Diasio, Robert B.

AU - Draetta, Giulio

AU - Frazier, A. Lindsay

AU - Futreal, Andrew

AU - Gambhir, Sam S.

AU - Ganz, Patricia A.

AU - Garraway, Levi

AU - Gerson, Stanton

AU - Gupta, Sumit

AU - Heath, James

AU - Hoffman, Ruth I.

AU - Hudis, Cliff

AU - Hughes-Halbert, Chanita

AU - Ibrahim, Ramy

AU - Jadvar, Hossein

AU - Kavanagh, Brian

AU - Kittles, Rick

AU - Le, Quynh Thu

AU - Lippman, Scott M.

AU - Mankoff, David

AU - Mardis, Elaine R.

AU - Mayer, Deborah K.

AU - McMasters, Kelly

AU - Meropol, Neal J.

AU - Mitchell, Beverly

AU - Naredi, Peter

AU - Ornish, Dean

AU - Pawlik, Timothy M.

AU - Peppercorn, Jeffrey

AU - Pomper, Martin G.

AU - Raghavan, Derek

AU - Ritchie, Christine

AU - Schwarz, Sally W.

AU - Sullivan, Richard

AU - Wahl, Richard

AU - Wolchok, Jedd D.

AU - Wong, Sandra L.

AU - Yung, Alfred

PY - 2017/11

Y1 - 2017/11

N2 - We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.

AB - We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.

UR - http://www.scopus.com/inward/record.url?scp=85032672086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032672086&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(17)30698-8

DO - 10.1016/S1470-2045(17)30698-8

M3 - Review article

C2 - 29208398

AN - SCOPUS:85032672086

SN - 1470-2045

VL - 18

SP - e653-e706

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 11

ER -

Future cancer research priorities in the USA: a Lancet Oncology Commission

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this